Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Runihol in NAFLD and Metabolic Syndrome
NCT02930161Phase 2Terminated
- Sponsor
- POLYSAN
- Start
- May 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of runihol in non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (3 arms), sponsored by POLYSAN. Primary endpoint: Proportion of responders to treatment at 102 days. Started May 2016; status: terminated.
02
Drugs
runihol
03
Conditions
non-alcoholic fatty liver disease (NAFLD)metabolic syndrome
Beyond the preview
Go deeper on NCT02930161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930161.